CompletedNot Applicable

Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP

France10 participantsStarted 2021-03-09

Plain-language summary

LASIK is a refractive surgery technique widely used in France. Postoperatively, the classic treatment after LASIK consists of instilling drops to reduce dry eyes. REPADROP® is an innovative eye drops stimulating corneal innervation. To date no study has quantified the improvement in dry eye syndrome and thus the quality of life of patients using REPADROP®.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Age over 18 * Planned bilateral LASIK surgery * Use of Repadrop as postoperative eye drops * Patient agreement to participate Exclusion Criteria: * History of corneal pathology * Diabetes * History of treatment with REPADROP® or CACICOL® or NGF® (other eye drops which are no longer available on the market to date but which would also improve corneal healing) * Ongoing treatment with topical cyclosporine * Presence of punctal plugs * Adults who are the subject of a legal protection measure (guardianship, curators) * Pregnant or breastfeeding women

What they're measuring

Variation in OSDI (Ocular Surface Disease Index) score

Timeframe: 3 Months

Trial details

NCT IDNCT04654455

SponsorHospices Civils de Lyon

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-11-02

View on ClinicalTrials.gov More Ametropia trials